罗西格利塔介导的PPARγ激活诱导PlGF表达在热原体细胞
Pinki Nandi1, Chidambra Halari1, Mavis Lee1
1Sunnybrook Research Institute, Toronto, ON, Canada.
Reproductive sciences (Thousand Oaks, Calif.)
|April 28, 2025
概括
罗西格利塔是一种PPARγ激动剂,在孕前 (PE) 模型中挽救了胎盘生长因子 (PlGF) 的产生. 这突出了PPARγ-GCM1-PlGF轴,并表明PPARγ激活可能改善PE怀孕结果.
科学领域:
- 产科和妇科 产科和妇科
- 分子生物学分子生物学
- 药理学 药理学是指药理学的学科.
背景情况:
- 孕前 (PE) 涉及胎盘血管功能障碍和受损的热囊细胞入侵.
- 胎盘生长因子 (PlGF) 对于胎盘血管生成至关重要,并由质细胞缺失-1 (GCM1) 和过氧体增殖器激活受体- (PPARγ) 调节.
- 降低PE中的PPARγ活性可能会降低PLGF,加剧胎盘病理.
研究的目的:
- 调查PPARγ激动剂罗西格利塔在PE模仿低氧压力下恢复PlGF表达中的作用.
- 阐明PPARγ,GCM1和PLGF在胎盘细胞中的机制性途径.
主要方法:
- 为了模仿PE条件,JEG-3热囊细胞接受了1.5%的氧气/再氧化.
- 细胞接受了罗西格利塔 (PPARγ 激动剂) 或T0070907 (抑制剂) 的治疗,并分析了PPARγ,GCM1,HO-1和PLGF表达.
- 通过siRNA介导的PPARγ被使用来确认其作用.
主要成果:
- 罗西格利塔促进了PPARγ的核转位,增加了GCM1和血红氧酶-1 (HO-1) 的表达.
- 在正常和缺氧条件下,罗西格利塔对plGF的产生进行了上调.
- 抑制PPARγ或敲击消除了罗西格利塔的作用,证实了PPARγ-GCM1-PlGF轴.
- 罗西格利塔治疗在低氧压力下的细胞中挽救了plgf水平.
结论:
- PPARγ-GCM1-PlGF信号通路对胎盘健康至关重要.
- 药理上激活PPARγ,使用诸如罗西格利塔之类的药物,显示出对孕前的治疗潜力.
- 准PPARγ可能提供一种策略,以改善孕前患者的妊娠结果.
相关概念视频
Cell Specific Gene Expression
13.3K
Multicellular organisms contain a variety of structurally and functionally distinct cell types, but the DNA in all the cells originated from the same parent cells. The differences in the cells can be attributed to the differential gene expression. Liver cells, whose functions include detoxification of blood, production of bile to metabolize fats, and synthesis of proteins essential for metabolism, must express a specific set of genes to perform their functions. Gene expression also varies with...
13.3K
TGF - β Signaling Pathway
7.2K
The TGF-β signaling pathway regulates cell growth, differentiation, adhesion, motility, and development. TGF-β ligands that induce TGF-β signaling are synthesized in their latent form. Several proteases or cell surface receptors such as integrins act upon the latent form, releasing the active ligand. There are three types of mammalian TGF-βs: (TGF-β1, TGF-β2, and TGF-β3) that bind as homodimers or heterodimers to TGF-β receptors. The TGF-β receptors...
7.2K
Glucagon-like Receptor Agonists
250
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
250
PI3K/mTOR/AKT Signaling Pathway
3.3K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.3K
GPCRs Regulate Adenylyl Cylase Activity
5.0K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.0K
Oral Hypoglycemic Agents: Biguanides and Glitazones
133
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
133


